Dongqing M. Lv
Taizhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 100 publications
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.
Journal: JAMA
Published: June 17, 2026
Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH).
Journal: Cancer biology & medicine
Published: May 22, 2026
Expert consensus on the detection and clinical application of tumor mutational burden.
Journal: Cancer biology & medicine
Published: February 18, 2026
Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 04, 2025
Anlotinib + Toripalimab maintenance in Extensive-Stage small cell lung Cancer: Clinical efficacy and preclinical mechanism of anlotinib-induced neuroendocrine differentiation Suppression via Notch1.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 01, 2025
Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational study.
Journal: Future oncology (London, England)
Published: October 30, 2025
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.
Journal: The Lancet regional health. Western Pacific
Published: October 30, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 09, 2025
Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.
Journal: Signal transduction and targeted therapy
Published: August 25, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 22, 2025
Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial.
Journal: Chinese medical journal
Published: August 12, 2025
Last Updated: 09/26/2026